RESUMEN
Objectives: To determine if resistance to topical treatments can be overcome under conditions promoting adherence.Materials and Methods: Twelve psoriasis patients treated with topical 0.25% desoximetasone spray were randomized to either twice daily phone call reminders or no phone call and were treated for 2 weeks. Pruritus Visual Analog Scale (VAS), Psoriasis Area and Severity Index (PASI), Total Lesion Severity Score (TLSS), and, Investigator Global Assessment (IGA) assessed disease severity.Results: Most subjects improved in most scoring parameters. 100%, 91.7%, 83.3%, and 58.3% had improvements in itching, PASI, TLSS, and IGA, respectively.Conclusions: While our sample size was small and treatment duration short, the effect size of topical treatment was large under conditions designed to promote adherence.
Asunto(s)
Desoximetasona/uso terapéutico , Glucocorticoides/uso terapéutico , Psoriasis/tratamiento farmacológico , Administración Tópica , Adulto , Anciano , Desoximetasona/efectos adversos , Esquema de Medicación , Femenino , Glucocorticoides/efectos adversos , Humanos , Masculino , Persona de Mediana Edad , Psoriasis/patología , Índice de Severidad de la Enfermedad , Resultado del TratamientoAsunto(s)
Antiinflamatorios/uso terapéutico , Desoximetasona/uso terapéutico , Hidroxizina/uso terapéutico , Mastocitosis/diagnóstico , Mastocitosis/patología , Adulto , Antiinflamatorios/administración & dosificación , Desoximetasona/administración & dosificación , Femenino , Humanos , Hidroxizina/administración & dosificación , Mastocitosis/tratamiento farmacológicoRESUMEN
Introduction: Topical corticosteroids, available in an array of vehicles are used to control a variety of inflammatory skin diseases. Patients preferences for different vehicles may affect their willingness to use treatment. We assess corticosteroid vehicle preference and potential impact of topical characteristics on adherence and quality of life in patients with psoriasis.Methods: Subjects with psoriasis were recruited from Wake Forest University Dermatology Clinic. Subjects sampled desoximetasone 0.25% spray, betamethasone valerate 0.1% cream, triamcinolone acetonide 0.1% ointment, fluocinonide 0.05% gel, betamethasone valerate 0.1% lotion, clobetasol propionate 0.05% foam, and fluocinonide 0.05% solution in a predetermined randomized order. Subjects completed a Vehicle Preference Measure, Determinants of Adherence Measure, and a Determinants of Quality of Life Measure.Results: Patients preferences for the various products were highly variable. Regarding Determinants of Adherence, patients perception of absorption of the medication was ranked as 'quite important/extremely important' by 85% of total subjects. A majority of patients rated medication side effects as 'quite important/extremely important' when asked to consider topical characteristics effect on quality of life.Discussion: There was wide variation in patient preference for topical medication vehicles used for treating psoriasis. Several vehicle characteristics were considered important to adherence. Given the marked variation in vehicle preference, topical treatment should be individualized according to patients preferences.
Asunto(s)
Glucocorticoides/uso terapéutico , Vehículos Farmacéuticos/química , Psoriasis/tratamiento farmacológico , Administración Tópica , Valerato de Betametasona/efectos adversos , Valerato de Betametasona/química , Valerato de Betametasona/uso terapéutico , Clobetasol/efectos adversos , Clobetasol/química , Clobetasol/uso terapéutico , Desoximetasona/efectos adversos , Desoximetasona/química , Desoximetasona/uso terapéutico , Composición de Medicamentos , Femenino , Fluocinonida/efectos adversos , Fluocinonida/uso terapéutico , Glucocorticoides/efectos adversos , Glucocorticoides/química , Humanos , Masculino , Persona de Mediana Edad , Prioridad del Paciente/psicología , Psoriasis/patología , Calidad de VidaRESUMEN
PURPOSE:: Topical corticosteroids (TS) are a treatment for atopic dermatitis (AD) and psoriasis (Ps). We assessed whether use of a TS under conditions designed to enhance adherence would be effective in patients who "failed" TS in the outpatient setting. METHODS:: Individuals with treatment-resistant Ps or AD were recruited (AD, n = 12; Ps, n = 12). Six participants were randomized to each of 2 groups of desoximetasone 0.25% spray alone (n = 6) or desoximetasone spray plus twice-daily phone call reminders to use the medication. Disease severity was assessed. RESULTS:: In treatment-resistant Ps patients, desoximetasone spray, with reminders, resulted in statistically significant improvement in all outcome measures. In treatment-resistant AD patients, there was statistically significant improvement in some assessments. Despite the very small sample size and short evaluation time, statistically significant changes were detected in this cohort. This is evidence of the large effect size of TS for Ps and AD when the treatment is used. CONCLUSIONS:: Patients with "treatment-resistant" Ps and AD generally responded well to the use of desoximetasone spray in the trial setting. This may be due to better adherence in the study environment or patients' preference for the spray vehicle. Patient reminders contributed to improved clinical outcomes in Ps and AD patients with "treatment-resistant" disease.
Asunto(s)
Antiinflamatorios/administración & dosificación , Dermatitis Atópica/tratamiento farmacológico , Desoximetasona/administración & dosificación , Psoriasis/tratamiento farmacológico , Sistemas Recordatorios , Administración Cutánea , Adulto , Anciano , Antiinflamatorios/uso terapéutico , Desoximetasona/uso terapéutico , Resistencia a Medicamentos , Femenino , Humanos , Masculino , Cumplimiento de la Medicación , Persona de Mediana Edad , Índice de Severidad de la Enfermedad , Teléfono , Adulto JovenRESUMEN
BACKGROUND: In extensive psoriasis, topical corticosteroids are generally only used to supplement phototherapy and systemic therapy. Spray formulations are easier than other vehicle preparations to apply and may be an option for treating extensive psoriasis. OBJECTIVE: To evaluate the potential for hypothalamic-pituitary-adrenal axis suppression and efficacy of topical desoximetasone 0.25% spray formulation in patients with extensive psoriasis. METHODS: A multicenter, open label, nonrandomized, clinical trial was conducted. Two groups of 12 adults with moderate to severe plaque-type psoriasis were treated with 0.25% desoximetasone spray for 28 days. Physician global assessment (PGA) and body surface area (BSA) were assessed. Cortisol-induced suppression test was performed at baseline, day 14 and day 28 to assess safety. RESULTS: No statistically significant difference was seen in adrenal suppression; odds ratio of 0.779 (p = .85). The mean PGA improvement from baseline was 1.83 and 1.33 for moderate and severe psoriasis, respectively. Mean BSA involvement at baseline for moderate and severe psoriasis was 11% and 23%, respectively, improving to 5% and 19%, respectively. CONCLUSIONS: Considerable improvement can be achieved with short-term potent topical corticosteroid treatment even in patients with severe, extensive psoriasis. For such use, topical desoximetasone has less risk of HPA-suppression than does topical clobetasol.
Asunto(s)
Fármacos Dermatológicos/uso terapéutico , Desoximetasona/uso terapéutico , Psoriasis/tratamiento farmacológico , Administración Tópica , Adolescente , Adulto , Anciano , Superficie Corporal , Composición de Medicamentos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Sistema Hipófiso-Suprarrenal , Índice de Severidad de la Enfermedad , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND: Traditionally, ointments were the vehicle of choice for psoriasis. Poor adherence of traditional vehicles limits the use of topical corticosteroids. Alternative formulations have gained popularity due to their ease of application, improved adherence and efficacy. OBJECTIVE: To evaluate the efficacy of topical desoximetasone 0.25% spray formulation in extensive psoriasis. METHODS: This multicenter, double-blinded, randomized trial compared twice daily topical 0.25% desoximetasone spray to placebo in subjects ≥18 with moderate to severe plaque psoriasis. Primary outcome of the study was the proportion of subjects in each group that achieved clinical success (Physician Global Assessment [PGA] of 0 or 1) and/or treatment success at (target lesion score of 0 or 1) day 28. RESULTS: One-hundred-and-twenty subjects were enrolled. At baseline, 75.0% and 73.3% of the treatment and placebo group had at least moderate PGA, respectively. Clinical success in the intended-to treat and placebo group was 30% and 5% (p = .0003), respectively; treatment success was 39% and 7% (p < .0001), respectively. LIMITATIONS: The lack of standardized outcomes for topical psoriasis treatments limits the ability to compare the results to other treatments. CONCLUSIONS: Topical desoximetasone spray provides rapid control of moderate to severe psoriasis lesions and may be considered for patients awaiting approval of biologicals. TRIAL REGISTRATION: Clinical Trial was registered at clinicaltrial.gov: NCT01206387.
Asunto(s)
Fármacos Dermatológicos/uso terapéutico , Desoximetasona/uso terapéutico , Psoriasis/tratamiento farmacológico , Administración Tópica , Adulto , Anciano , Anciano de 80 o más Años , Método Doble Ciego , Esquema de Medicación , Composición de Medicamentos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Efecto Placebo , Psoriasis/patología , Índice de Severidad de la Enfermedad , Resultado del Tratamiento , Adulto JovenRESUMEN
Data from two Phase 3, double-blind, randomized, vehicle-controlled parallel studies were evaluated to determine the efficacy and safety of twice daily desoximetasone 0.25% spray for the treatment of plaque psoriasis. In addition to global disease assessments, scaling assessments were performed at baseline and at weeks 1, 2, and 4. To qualify for inclusion, subjects were required to have a clinical diagnosis of stable plaque psoriasis involving ≥10% of the body surface area (BSA), a combined target lesion severity score (TLSS) of ≥7 for the target lesion, a plaque elevation score of ≥3 (moderate) for the target lesion, and a Physician Global Assessment (PGA) score of 3 (moderate) or 4 (severe) at baseline for the overall disease severity. At the baseline visit, the mean proportions of BSA affected by psoriasis were 17% (range 10% to 86%) in the desoximetasone 0.25% spray group and 16% (range 10% to 70%) in the vehicle spray group. Approximately 90% of the patients in each group had moderate to very severe scaling at baseline. Desoximetasone 0.25% spray was effective with significant improvements in overall severity and was well tolerated, with dryness, irritation, and pruritus at the application site being the only reported adverse events occurring in >1% of patients, each of which occurred in less than 3% of patients. As a large proportion of psoriasis patients (94%) have reported being bothered by scaling, the relief of scaling was examined in these studies. At week 1, 69.7% of patients on desoximetasone 0.25% spray had scaling that was considered clear / almost clear / mild compared with 48.3% for those on vehicle spray ( P = .0027). By week 4, the proportion of patients with clear / almost clear / mild scaling had risen to 83.9% in the desoximetasone 0.25% spray group (P < .0001). After four weeks of treatment, 66.4% of patients in the topical corticosteroid group had an overall improvement of at least two grades of disease severity. This demonstrates that desoximetasone 0.25% spray provided fast and effective relief of scaling in patients with plaque psoriasis affecting 10% to 86% of their BSA.
Asunto(s)
Antiinflamatorios/uso terapéutico , Desoximetasona/uso terapéutico , Psoriasis/tratamiento farmacológico , Adolescente , Adulto , Anciano , Antiinflamatorios/administración & dosificación , Superficie Corporal , Desoximetasona/administración & dosificación , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Psoriasis/patología , Índice de Severidad de la Enfermedad , Resultado del Tratamiento , Adulto JovenAsunto(s)
Náusea/tratamiento farmacológico , Antagonistas de la Serotonina/uso terapéutico , Vómitos/tratamiento farmacológico , Desoximetasona/uso terapéutico , Granisetrón/uso terapéutico , Humanos , Indoles/uso terapéutico , Isoquinolinas/uso terapéutico , Ondansetrón/uso terapéutico , Palonosetrón , Quinolizinas/uso terapéutico , Quinuclidinas/uso terapéutico , Antagonistas de la Serotonina/efectos adversosRESUMEN
Two Phase 3, double-blind, randomized, vehicle-controlled parallel studies evaluated the efficacy and safety of desoximetasone spray 0.25%, a super-potent topical corticosteroid, twice daily vs vehicle spray twice daily for 28 days in adult patients with moderate to severe plaque psoriasis. At baseline and throughout the study, the severity of disease for the psoriatic lesions was assessed using the Physician Global Assessment (PGA) score and a target lesion was assessed using the Total Lesion Severity Score (TLSS). A designated psoriatic plaque lesion was selected as the target lesion upon enrollment and evaluated throughout the study to determine the TLSS. To qualify for study entry, the subject needed to exhibit a PGA score of 3 (moderate) or 4 (severe) for overall disease severity, and a target lesion with an area of at least 5 cm(2) that achieved a combined score TLSS of >=7, with a plaque elevation score of >=3 (at least moderate). The mean % BSA affected by psoriasis ranged from 13%-17% at baseline. In both Phase 3 studies, a statistically significantly greater percentage of subjects in the desoximetasone spray 0.25% compared to vehicle group achieved both Clinical Success and Treatment Success at Day 28. These results, which were the primary efficacy variables, demonstrated superior efficacy in the active study group for both overall improvement of plaque psoriasis (by PGA) and in the individual psoriasis lesion (by TLSS) designated at baseline as the most severely involved plaque (target lesion). Assessment of secondary efficacy variables in both Phase 3 studies showed that subjects receiving desoximetasone Spray 0.25% twice daily exhibited statistically significantly mean changes from Baseline to Day 28 in PGA, TLSS, and % BSA affected when compared to subjects receiving vehicle spray twice daily. Tolerability and safety were assessed at all study visits. No statistically significant differences were observed between study arms and no major safety signals related to AEs were noted. No stinging and burning were reported with the spray formulation. This Class I topical corticosteroid has shown to be safe and efficacious in moderate to severe plaque psoriasis.
Asunto(s)
Fármacos Dermatológicos/uso terapéutico , Desoximetasona/uso terapéutico , Glucocorticoides/uso terapéutico , Psoriasis/tratamiento farmacológico , Administración Cutánea , Adulto , Anciano , Anciano de 80 o más Años , Fármacos Dermatológicos/administración & dosificación , Fármacos Dermatológicos/efectos adversos , Desoximetasona/administración & dosificación , Desoximetasona/efectos adversos , Método Doble Ciego , Femenino , Glucocorticoides/administración & dosificación , Glucocorticoides/efectos adversos , Humanos , Masculino , Psoriasis/patología , Índice de Severidad de la Enfermedad , Resultado del Tratamiento , Adulto JovenRESUMEN
Acrodermatitis continua of Hallopeau (ACH) is a rare disease. Little is known about its etiology or relative effectiveness of the various therapeutic approaches. However, in the literature a pattern seems to be developing on successfully treated patients using biologic therapies. Here, we further emphasize the potential breakthrough presented by the novel immune based therapies. This report consists of a case of etanercept responsive ACH along with a brief review of the literature.
Asunto(s)
Acrodermatitis/tratamiento farmacológico , Antiinflamatorios/uso terapéutico , Desoximetasona/uso terapéutico , Inmunoglobulina G/uso terapéutico , Receptores del Factor de Necrosis Tumoral/uso terapéutico , Proteínas Recombinantes de Fusión/uso terapéutico , Factor de Necrosis Tumoral alfa , Acrodermatitis/diagnóstico , Acrodermatitis/patología , Administración Cutánea , Anciano , Antiinflamatorios/administración & dosificación , Desoximetasona/administración & dosificación , Diagnóstico Diferencial , Quimioterapia Combinada , Etanercept , Humanos , MasculinoRESUMEN
OBJECTIVE: The psoriasis is chronic disease characterized from an acceleration of the kinetic of the cells of epidermis. To front of the empirical evidence of the benefits of the thermal therapy in the psoriasis, the experimentals-clinics studies is insufficient. The aim of research it has been that of quantify the benefits of the mud-bath therapy with mineral water in the psoriasis. PATIENT AND METHODS: The study has been channel on a champion of 30 subjects of which 19 of male sex and 11 of female sex with middle equal age to 56 years +/- 5.3 affected from psoriasis. The subjects of the examined champion have been divided to random in 2 groups: A and B. The group A has been treated with drugs used for psoriasis for 12 days; the B group has been treated, always for 12 consecutive days, with mud-bath therapy (FBT) with mineral water obtained from the mineral sources (chlorinate-sulphureous-bicarbonate) of the Spa of Stabia in Castellammare (NA). To the beginning and at the end of the advised treatments has been valued the prurient symptomatology and the PASI (Psoriasis and Severity Index). RESULTS: The data highlight an significant (P < 0.05) reduction is of the prurient symptomatology and of the PASI in both the groups considered. CONCLUSIONS: The results of this first step of investigations seems to highlight that the FBT treatment, to the same way of the drugs anti-psoriasis, results useful in the ameliorate the quality of life of these patients.
Asunto(s)
Peloterapia , Psoriasis/terapia , Antiinflamatorios/administración & dosificación , Antiinflamatorios/uso terapéutico , Clobetasol/administración & dosificación , Clobetasol/uso terapéutico , Ciclosporina/administración & dosificación , Ciclosporina/uso terapéutico , Fármacos Dermatológicos/administración & dosificación , Fármacos Dermatológicos/uso terapéutico , Desoximetasona/administración & dosificación , Desoximetasona/uso terapéutico , Quimioterapia Combinada , Femenino , Glucocorticoides/administración & dosificación , Glucocorticoides/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Aguas Minerales/uso terapéutico , Furoato de Mometasona , Pomadas , Pregnadienodioles/administración & dosificación , Pregnadienodioles/uso terapéutico , Psoriasis/diagnóstico , Psoriasis/tratamiento farmacológico , Calidad de Vida , Retinoides/administración & dosificación , Retinoides/uso terapéutico , Muestreo , Factores de Tiempo , Resultado del Tratamiento , Vitamina D/administración & dosificación , Vitamina D/uso terapéuticoRESUMEN
The physical and chemical compatibility of desoximetasone ointment 0.25% and tacrolimus ointment 0.1%, both widely used to treat atopic dermatitis, were determined. A 1:1 (w/w) mixture of desoximetasone ointment 0.25% (Topicort, Taro Pharmaceuticals USA, Inc.) and tacrolimus ointment 0.1% (Protopic, Fujisawa Healthcare, Inc.) were prepared and stored under three different temperature/relative humidity conditions: 25 degrees C/60% RH; 30 degrees C/60% RH; and 40 degrees C/75% RH. Unmixed ointments stored under the same temperature and humidity conditions as the mixture served as controls. Samples were evaluated at days 1, 2, 7, 14, and 28 for color, degree of physical separation, and chemical stability via reverse-phase high performance liquid chromatography. Ranges of relative recovery for each active ingredient for all storage conditions ((% Mixture/% Control) x 100) were 89.6-109.3% for tacrolimus and 99.0-103.4% for desoximetasone. No significant difference in physical appearance or chromatographic profile between the mixture and controls was observed. Therefore, we conclude that desoximetasone ointment 0.25% (Topicort) and tacrolimus ointment 0.1% (Protopic) are physically and chemically compatible up to four weeks when mixed in a ratio of 1:1 (w/w).
Asunto(s)
Antiinflamatorios/química , Dermatitis Atópica/tratamiento farmacológico , Desoximetasona/química , Inmunosupresores/química , Tacrolimus/química , Administración Cutánea , Antiinflamatorios/administración & dosificación , Antiinflamatorios/uso terapéutico , Química Farmacéutica , Desoximetasona/administración & dosificación , Desoximetasona/uso terapéutico , Estabilidad de Medicamentos , Quimioterapia Combinada , Humanos , Inmunosupresores/administración & dosificación , Inmunosupresores/uso terapéutico , Pomadas/administración & dosificación , Tacrolimus/administración & dosificación , Tacrolimus/uso terapéuticoRESUMEN
The nonhalogenated double ester of prednisolone, prednicarbate (PC), is the first topical glucocorticoid with an improved benefit/risk ratio verified clinically and in vitro. To evaluate if this is due to unique characteristics of this steroid, a new compound created according to an identical concept, prednisolone 17-ethylcarbonate, 21-phenylacetate (PEP), and the new halogenated monoester desoximetasone 21-cinnamate (DCE) were tested and compared to PC, desoximetasone (DM) and betamethasone 17-valerate (BMV). Isolated foreskin keratinocytes served for in vitro investigations of anti-inflammatory processes in the epidermis, fibroblasts of the same origin were used to investigate the atrophogenic potential. Inflammation was induced by TNFalpha, resulting in an increased interleukin 1alpha (Il-1alpha) synthesis. As quantified by ELISA, all drugs significantly reduced Il-1alpha production. But PC and BMV appeared particularly potent, followed by DM and the two new congeners, which revealed minor anti-inflammatory activity. Glucocorticoid esters including PEP are rapidly degraded in keratinocytes (85% within 12 h). Hence, a ribonuclease protection assay of Il-1alpha mRNA was performed allowing short incubation times and thus minimizing biodegradation. This assay confirmed the anti-inflammatory potency of native PC and BMV. In contrary DCE and PEP did not reduce Il-1alpha mRNA to a significant extent. Therefore PEP acts as a prodrug only. In fibroblasts, Il-1alpha and Il-6 syntheses indicate proliferation and inflammation, respectively. Whereas PC and PEP inhibited Il-1alpha and Il-6 production in fibroblasts only to a minor extent, cytokine synthesis was strongly affected by the conventional glucocorticoids BMV and DM, but also by DCE. The minor unwanted effect of PC and PEP on fibroblasts was also reflected by their low influence on cell proliferation as derived from (3)H-thymidine incorporation. Again, more pronounced antiproliferative features were seen with the halogenated glucocorticoids. In the following, the correlation between antiphlogistic effects in keratinocytes (suppression of Il-1alpha) and antiproliferative effects in fibroblasts (suppression of Il-1alpha and Il-6; (3)H-thymidine incorporation) was analyzed. Here, PC is revealed as the only glucocorticoid with an improved benefit/risk ratio. Native PEP is shown to be almost ineffective and DCE presents exactly the opposite features of PC. It is tempting to speculate if this is due to different glucocorticoid receptor subtypes or different signaling pathways in keratinocytes and fibroblasts.
Asunto(s)
Antiinflamatorios/farmacología , Dermatitis/tratamiento farmacológico , Dermatitis/patología , Administración Tópica , Antiinflamatorios/uso terapéutico , División Celular/efectos de los fármacos , Células Cultivadas , Colorantes , Desoximetasona/metabolismo , Desoximetasona/farmacología , Desoximetasona/uso terapéutico , Ensayo de Inmunoadsorción Enzimática , Glucocorticoides , Humanos , Interleucinas/biosíntesis , Queratinocitos/efectos de los fármacos , FN-kappa B/biosíntesis , Prednisolona/análogos & derivados , Prednisolona/metabolismo , Prednisolona/farmacología , Prednisolona/uso terapéutico , Biosíntesis de Proteínas , ARN Mensajero/biosíntesis , Ribonucleasas/antagonistas & inhibidores , Medición de Riesgo , Transducción de Señal/efectos de los fármacos , Piel/citología , Piel/efectos de los fármacos , Piel/patología , Sales de Tetrazolio , Tiazoles , Timidina/metabolismoRESUMEN
The hairless mouse model of a UVA-induced dermal neutrophilic infiltrate was used to compare the efficacy of equal concentrations of name brand versus generic corticosteroids. The generic brand was significantly less effective in suppressing the inflammatory response.
Asunto(s)
Desoximetasona/farmacología , Desoximetasona/uso terapéutico , Traumatismos Experimentales por Radiación/tratamiento farmacológico , Piel/efectos de los fármacos , Rayos Ultravioleta , Administración Cutánea , Animales , Movimiento Celular , Medicamentos Genéricos , Ratones , Ratones Pelados , Modelos Biológicos , Neutrófilos/efectos de los fármacos , Neutrófilos/patología , Neutrófilos/efectos de la radiación , Traumatismos Experimentales por Radiación/etiología , Piel/efectos de la radiación , Equivalencia Terapéutica , Factores de TiempoRESUMEN
The efficacy and acceptability of 0.25% and 0.05% desoxymethasone, 0.1% betamethasone valerate and 1% hydrocortisone creams were compared in patients with eczema. A double-blind parallel group multi-centre design was employed in which 96 patients were recruited by four centres. Patients used one cream for a 3-week period and follow-up assessment visits were made at weekly intervals. Efficacy variables were: erythema/redness, scaling, itching and extent of area affected. These variables were assessed by both the investigator and the patient. The 0.25% desoxymethasone was the most effective treatment, producing the greatest degree of improvement in all clinical parameters, hydrocortisone was the least effective and 0.05% desoxymethasone was of intermediate effectiveness. The 0.1% betamethasone produced similar results to 0.25% desoxymethasone for half the assessments; for the other half the results were similar to 0.05% desoxymethasone. No adverse effects were reported during the study. The results are discussed in terms of physical properties of the vehicles and corticosteroid potency.
Asunto(s)
Antiinflamatorios/uso terapéutico , Valerato de Betametasona/administración & dosificación , Betametasona/análogos & derivados , Desoximetasona/administración & dosificación , Dexametasona/análogos & derivados , Eccema/tratamiento farmacológico , Administración Tópica , Adolescente , Adulto , Anciano , Valerato de Betametasona/uso terapéutico , Niño , Preescolar , Ensayos Clínicos como Asunto , Comportamiento del Consumidor , Desoximetasona/uso terapéutico , Método Doble Ciego , Femenino , Humanos , Hidrocortisona , Masculino , Persona de Mediana Edad , Pomadas , Distribución AleatoriaRESUMEN
A psoriasis patient developed erythroderma after the withdrawal of a self-administered chronic topical glucocorticoid therapy. A marked expansion of cells with the morphological and phenotypic features of large granular lymphocytes was noticed in peripheral blood. Functional investigations revealed that these cells responded poorly to polyclonal activators and exhibited antibody-dependent cellular cytotoxicity and natural killer activity. Blood abnormalities completely subsided in about two months in the absence of any cytostatic therapy and coincided with the recovery from the erythroderma and the spreading of classical psoriatic plaque lesions. This excluded an underlying malignant process. This patient represents the first report of a previously undescribed immunological disorder in psoriatic erythroderma.
Asunto(s)
Dermatitis Exfoliativa/inmunología , Linfocitos/ultraestructura , Psoriasis/inmunología , Adulto , Dermatitis Exfoliativa/sangre , Desoximetasona/uso terapéutico , Humanos , Linfocitos/inmunología , Masculino , Microscopía Electrónica , Psoriasis/sangre , Psoriasis/tratamiento farmacológicoRESUMEN
Prednisolone-17-ethyl carbonate-21-propionate (PrEP, Hoe 777) was tested for antiinflammatory activity in various animal models by topical and systemic administration. In those models being indicative of topical efficacy, the potency of PrEP was the same as that of desoximetasone. However, systemic effects after topical administration of PrEP in shaved skin of the dorsum of rats were relatively weak compared with the reference compound. Moreover, there were less systemic corticoid effects after s.c. administration of PrEP than after desoximetasone. Thus, PrEP is obviously a compound with a considerable split of topical and systemic activity, suggesting its testing in man for systemic effects after topical administration.
Asunto(s)
Antiinflamatorios/uso terapéutico , Dermatitis/tratamiento farmacológico , Prednisolona/análogos & derivados , Administración Tópica , Animales , Antiinflamatorios/toxicidad , Desoximetasona/uso terapéutico , Gluconeogénesis/efectos de los fármacos , Granuloma/tratamiento farmacológico , Ratones , Ratones Endogámicos , Prednisolona/uso terapéutico , Prednisolona/toxicidad , Ratas , Ratas Endogámicas , Piel/efectos de los fármacosRESUMEN
We report on the clinical efficacy of the local corticoid prednicarbate (chemical name: prednisolone-17-ethyl carbonate-21-propionate). In a concentration of 0.25%, it can be assigned to corticoid force class III. We think it's remarkable that even extensive application of 20 g daily in patients with affected skin and 30 g daily in healthy persons does not cause any suppression of plasma cortisol. Extreme long-term application (12 months) in 4 test persons did not result in any clinical, histological, or electron microscopical signs of topical atrophy; only one case showed slight hypertrichosis. These studies show that we may regard the original opinion as disproved that efficacy and side effects of corticoids are always inseparably linked together. To our minds, this preparation constitutes an essential step towards solving the problem of long-term application of a topical corticoid wherever it may be necessary from the dermatologic point of view, e.g. especially in atopic dermatitis and psoriasis.
Asunto(s)
Antiinflamatorios/uso terapéutico , Dermatitis/tratamiento farmacológico , Prednisolona/análogos & derivados , Administración Tópica , Adolescente , Adulto , Anciano , Valerato de Betametasona/uso terapéutico , Niño , Cortisona/análogos & derivados , Cortisona/uso terapéutico , Dermatitis Atópica/tratamiento farmacológico , Dermatitis por Contacto/tratamiento farmacológico , Desoximetasona/uso terapéutico , Método Doble Ciego , Evaluación de Medicamentos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Prednisolona/uso terapéutico , Psoriasis/tratamiento farmacológicoRESUMEN
A double-blind, multicenter study was conducted to evaluate and compare the safety and efficacy of desoximetasone gel 0.05% and fluocinonide gel 0.05% in patients with scalp psoriasis. One hundred twenty-five patients were enrolled in this randomized, parallel-group trial. Responses based on clinical assessment in 123 patients showed that the desoximetasone gel formulation is a safe and effective treatment for psoriasis of the scalp. Although efficacy appears equivalent to that of fluocinonide gel 0.05% in treating psoriasis of the scalp, desoximetasone appears to be slightly better tolerated and better accepted cosmetically.